Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kura OncologyFRA:KUR -5.38%36 Shareholder Yield % is -0.37% as of Mar. 2026. GuruFocus rates FRA:KUR with a GF Score™ of 36/100. The stock has 7 warning signs investors should review. Among 1,297 Biotechnology companies, Kura Oncology ranks better than 57.59% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Kura Oncology's Shareholder Yield % was -0.37%.
Kura Oncology (FRA:KUR) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Kura Oncology Shareholder Yield % Related Terms
Kura Oncology Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Kura Oncology's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:KUR vs REPL, AVTX, SANA: Shareholder Yield % Comparison
For the Biotechnology subindustry, Kura Oncology's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kura Oncology Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kura Oncology's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Kura Oncology's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Kura Oncology (FRA:KUR) has a Shareholder Yield % of -0.37% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kura Oncology and its competitors. According to the industry distribution chart, Kura Oncology ranks #550 out of 1297 companies in the Biotechnology industry, placing it in the top 42.4%.
Is Kura Oncology's Shareholder Yield % too high?
Kura Oncology's current Shareholder Yield % is -0.37%. Based on the distribution chart, Kura Oncology ranks #550 out of 1297 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kura Oncology has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's Shareholder Yield % compare to REPL and AVTX?
According to the Biotechnology industry distribution chart, Kura Oncology ranks #550 out of 1297 companies for Shareholder Yield %. This puts Kura Oncology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kura Oncology and its competitors. Kura Oncology's current Shareholder Yield % is -0.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (FRA:KUR) has a current Shareholder Yield % of -0.37%. The current Shareholder Yield % is -0.37%. Kura Oncology's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Kura Oncology (FRA:KUR), the current Shareholder Yield % is -0.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
36GF Score
Get the complete analysis for FRA:KUR
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KUR has been successfully added to your 
